Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
about
Tensor GSVD of patient- and platform-matched tumor and normal DNA copy-number profiles uncovers chromosome arm-wide patterns of tumor-exclusive platform-consistent alterations encoding for cell transformation and predicting ovarian cancer survivalGSVD comparison of patient-matched normal and tumor aCGH profiles reveals global copy-number alterations predicting glioblastoma multiforme survivalPromoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a referenceBoron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potentialRecent advances in the molecular understanding of glioblastomaMalignant gliomas: old and new systemic treatment approachesNomograms in oncology: more than meets the eyeModern brain tumor imagingClinical outcomes following salvage Gamma Knife radiosurgery for recurrent glioblastoma.Long-term temozolomide might be an optimal choice for patient with multifocal glioblastoma, especially with deep-seated structure involvement: a case report and literature reviewPlatform-Independent Genome-Wide Pattern of DNA Copy-Number Alterations Predicting Astrocytoma Survival and Response to Treatment Revealed by the GSVD Formulated as a Comparative Spectral DecompositionLongitudinal quality of life data: a comparison of continuous and ordinal approaches.Standardized data collection to build prediction models in oncology: a prototype for rectal cancer.Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas.The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group sEfficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma.Polysialic acid neural cell adhesion molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines.Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice.Different molecular patterns in glioblastoma multiforme subtypes upon recurrenceQuantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma.Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastomaDNA methylation in glioblastoma: impact on gene expression and clinical outcomeRadiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era.O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction.Improved survival time trends for glioblastoma using the SEER 17 population-based registries.Multi-institutional validation of a preoperative scoring system which predicts survival for patients with glioblastoma.Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapiesThe proteomic response in glioblastoma in young patientsPrognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy.Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004.Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region.DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide.Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma.Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.Elderly patients affected by glioblastoma treated with radiotherapy: the role of serum hemoglobin level.Decreased survival in glioblastomas is specific to contact with the ventricular-subventricular zone, not subgranular zone or corpus callosum.Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme.Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levelsGreater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
P2860
Q21090556-19D74E36-0458-4BB6-A0C4-6D37FB68F3BFQ21090956-9A6735B6-A2A1-49D5-A6BC-84F180BC8985Q21261312-9AEDC352-A6C2-4409-839C-373375AD55A8Q24628726-19F5C0B3-A0A0-434E-A74A-2885126D58A0Q24632928-A67A4D3E-9408-4811-82A7-A32FEB720958Q26744387-999792F7-695D-4E11-B252-F3C3E44B0C3CQ26830260-17F11D7B-EE3A-4F83-B6DD-BFC3ADCC7678Q27002344-FFB3F26B-EF37-4FB1-93B4-AB361891417BQ27016552-36CFAAD4-E3C2-4FF7-96F2-290B4B741463Q27026704-A80515AF-47D6-40D6-BD43-B4B4D20F4172Q29300552-A051B5B5-4633-4B19-A69B-081A2BF0353AQ30829260-F93DD314-3C0D-40C3-B052-BF6CB02CA09BQ31032455-378FD4D2-A746-4A9D-A95B-E8316D4B305DQ31043472-71D6FBAD-4A42-42E3-ADEF-5ADEA695F661Q31117641-E6069A4F-D18C-4357-A587-B86AA4ED7FB4Q33392078-C40964FB-8BD6-4F4E-BB0C-BF56A12276E8Q33539425-36FAF5FE-CA4B-4F59-BB96-B83EC6742490Q33599200-B37E5509-0359-4055-97E9-1BAB198339CFQ33611551-1FDD0700-B173-47DC-B998-564BFC9EB63FQ33625236-875BB52D-F44A-429D-A280-1C67D0705541Q33708309-65C384AC-1654-4FF0-AC49-36A990F6DAE9Q33771159-DCA20779-AF8F-42F0-90D8-58575B92F2D5Q33779136-07CC65BC-A392-4F95-B49E-B34D6EFEC8C3Q33804528-D78978D8-A996-4489-BCE3-C02CDE008F88Q33828439-5E1EE7ED-8EAD-445B-B8CC-BBBAC731DC1DQ33862791-01C1DC0B-9A53-416E-ACB4-93E4419A0895Q33925544-D8A42309-171C-41EB-839A-C65F2A86098AQ34030167-A48FFD8D-27BD-49D9-9CB8-4A0BFFDF50C4Q34048935-54434813-5196-48EF-802E-99FBA43FD6A2Q34132950-3211C760-9A58-4AF6-9B54-344481BBBC89Q34132971-383B1B25-1359-4894-BD12-51427C85DFC8Q34168829-6155AF28-2458-48C1-99F1-CD161598E764Q34215037-9EDC2C10-5A06-4278-8FC2-033D6667A0BBQ34234748-07ACC52D-2964-4556-BBC3-CC2BEB4D50F4Q34242939-6B807826-807F-4A22-A66D-3D09B7898868Q34461414-7D32952C-B9C2-4BA4-9907-B97D091A0954Q34548971-56EBECBF-0554-46CE-8126-278B8D7CDB9FQ34587527-4361167C-90AA-4C0A-B4EB-71B9F3C14D36Q34712254-BCE5A001-7CE1-4C02-883E-8D8A8F692581Q34722415-F7B93176-086D-4D24-A7C0-F93611960C7F
P2860
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Nomograms for predicting survi ...... d NCIC trial 26981-22981/CE.3.
@en
type
label
Nomograms for predicting survi ...... d NCIC trial 26981-22981/CE.3.
@en
prefLabel
Nomograms for predicting survi ...... d NCIC trial 26981-22981/CE.3.
@en
P2093
P50
P1433
P1476
Nomograms for predicting survi ...... d NCIC trial 26981-22981/CE.3.
@en
P2093
Anouk Allgeier
Denis Lacombe
Elizabeth Eisenhauer
J Gregory Cairncross
Karl Belanger
Michael Weller
René O Mirimanoff
Roger Stupp
Thierry Gorlia
P356
10.1016/S1470-2045(07)70384-4
P577
2007-12-21T00:00:00Z